| Literature DB >> 29710505 |
Mohammad Hasan Soheilifar1, Ramezan Ali Taheri2, Reza Zolfaghari Emameh3, Abdolvahab Moshtaghian4, Hamid Kooshki5, Mohammad Reza Motie6.
Abstract
Alveolar soft part sarcoma (ASPS) is a highly aggressive rare soft tissue sarcoma (STS) with poor prognosis especially in the metastatic form. ASPS is resistant to standard chemotherapy. Although, early diagnosis and surgical resection of operable tumor could lead to improved patient survival but novel treatment options are needed for advanced (metastatic) ASPS. This malignancy exhibits highly angiogenic behavior which reflects hyper-activation and over expression of angiogenic factors. Understanding the molecular events in this type of sarcoma is important in finding novel molecular based targeted therapies. We aim to review molecular aspects of ASPS growth and treatment.Entities:
Keywords: Alveolar soft part sarcoma; Drug resistance; Molecular targeted therapy; Tyrosine kinase inhibitor
Mesh:
Substances:
Year: 2018 PMID: 29710505 DOI: 10.1016/j.biopha.2018.04.117
Source DB: PubMed Journal: Biomed Pharmacother ISSN: 0753-3322 Impact factor: 6.529